Literature DB >> 12843222

Coming of age: recombinant human thyroid-stimulating hormone as a preparation for (131)i therapy in thyroid cancer.

Richard J Robbins1, Keith S Pentlow.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843222

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  2 in total

1.  Radioactive body burden measurements in (131)iodine therapy for differentiated thyroid cancer: effect of recombinant thyroid stimulating hormone in whole body (131)iodine clearance.

Authors:  Ramamoorthy Ravichandran; Amal Al Saadi; Naima Al Balushi
Journal:  World J Nucl Med       Date:  2014-01

2.  Microscopic Positive Tumor Margin Increases Risk for Disease Persistence but Not Recurrence in Patients with Stage T1-T2 Differentiated Thyroid Cancer.

Authors:  Olfat Kamel Hasan; Sarah De Brabandere; Irina Rachinsky; David Laidley; Danielle MacNeil; Stan Van Uum
Journal:  J Thyroid Res       Date:  2020-01-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.